Letter to the Editor

Response to Drs. Phillips and Heavner

Authors: Ziad Arabi, MD

Abstract

To the Editor:


I would like to thank Dr. Phillips and Dr. Heavner for their review. However, I would like to clarify a few points that they made.


First of all, Dr. Phillips and Dr. Heavner listed in their letter as a correction that “The smokeless tobacco (ST) products used in India often contain lime or betel (areca) nut in addition to tobacco and the epidemiologic evidence suggests that they are far more harmful than the modern western smokeless products used in North America and Sweden.” While this is a well-known fact, it has no reference to the material presented in the article that addresses the ST in the United States.1

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Arabi Z. An epidemic that deserves more attention: Epidemiology, prevention, and treatment of smokeless tobacco. South Med J 2007;100:890–894.
 
2. Hensley SJ, Connell CJ, Richter P, et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control 2007;16:22–28.
 
3. Henley SJ, Thun MJ, Connell C, et al. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 2005;16:347–358.
 
4. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. Lancet 2006;368:647–658.
 
5. Bolinder G, Alfredsson L, Englund A, et al. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am J Public Health 1994;84:399–404.
 
6. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994;154:989–995.
 
7. Kimmel SE, Berlin JA, Miles C, et al. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001;37:1297–1302.
 
8. Benowitz NL. Nicotine and smokeless tobacco. Cancer J Clin 1988;38:244–247.
 
9. Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc 2005;80:652–658.
 
10. Tilashalski K, Rodu B, Cole P. Seven year follow-up of smoking cessation with smokeless tobacco. J Psychoactive Drugs 2005;37:105–108.
 
11. Arabi Z. The Metabolic and Cardiovascular Effects of Smokeless Tobacco. J of the CardioMetabolic Syndrome 2006;1:345–350.